Business Wire

NY-SONIC-ENTERPRISES

Share
World-Renowned and Globally Recognized Photographer Anne Geddes Brings Her Artistry and Creativity to NFTs for the First Time With Her Mother’s Day 2022 Collection

Anne Geddes , photographer globally renowned for her iconic imagery capturing the beauty, purity, and joy of new life, brings her artistry and creativity to NFTs for the first time. On May 6, 2022, the Anne Geddes Mother’s Day 2022 NFT Collection will drop at 9 a.m. PT, commemorating the holiday. The Collection contains nine selections made available in a variety of format configurations. Her highly anticipated collection will be sold exclusively through the certified carbon-neutral blockchain marketplace WAX and powered by the Shopify app Waxify . Her renowned artwork will be available for purchase in FIAT (USD) through credit card, PayPal and other traditional payments as well as WAXP, Bitcoin, and Ethereum. This crossover collection seamlessly bridges the gap between the mainstream Anne Geddes photography collectors and avid NFT collectors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220502005269/en/

Buyers can pre-register for the sale at annegeddes.io , with a pre-sale beginning a day prior — May 5, 2022, at 9 a.m. PT.

The configurations of the collection include:

Limited Edition Digital Prints:

All nine images in the Mother's Day collection are minted as digital art prints. Every digital print can be "redeemed" for a corresponding physical 8”x10” print.

Signature Series:

All nine images from the collection make up the “Signature Series.” Every digital print will feature an original authenticated digital signature and a signed physical print. Only 20 of each print will be available for a total of 180 prints. These prints are created exclusively for the Anne Geddes Mother’s Day 2022 NFT Collection.

1-of-1 Collection:

Two images from the collection will be available as limited edition one-of-one digital and physical prints. Each image will feature an authenticated original digital signature and a signed one-of-a-kind physical print.

Each artfully minted NFT will come with an exclusive redemption offering for a physical piece of art, made exclusively for this release. Every NFT will also contain a minted video of Anne personally discussing each of the images. Additionally, all digital and physical prints will be made exclusively for this release and will not be made again in this format.

Anne will also be auctioning off one elusive private shoot in her studio in New York to raise money for mothers and children in Ukraine. An additional commemorative NFT to support Ukrainian children will be available in the gallery to help raise additional funds. All proceeds will be provided to The American Red Cross.

While Anne’s photography has been treasured and respected by many generations, her evocative move into the blockchain with an iconic Anne Geddes Mother's Day NFT Collection is groundbreaking for an artist of this caliber.

Link:

ClickThru

Social Media:

https://www.facebook.com/annegeddes

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye